Pre-clinical evaluation of a 15-valent pneumococcal conjugate vaccine (PCV15-CRM197) in an infant-rhesus monkey immunogenicity model |
| |
Authors: | Skinner Julie M Indrawati Lani Cannon Jayme Blue Jeffrey Winters Michael Macnair John Pujar Narahari Manger Walter Zhang Yuhua Antonello Joseph Shiver John Caulfield Michael Heinrichs Jon H |
| |
Institution: | a Department of Vaccines Research, Merck & Co., Inc., West Point, PA 19486, USA b Department of Vaccine Drug Product Development and New Technologies, Merck & Co., Inc., West Point, PA 19486, USA c Department of Bioprocess Research & Development, Merck & Co., Inc., West Point, PA 19486, USA d Department of Non-clinical Statistics, Merck & Co., Inc., West Point, PA 19486, USA |
| |
Abstract: | The incidence of invasive pneumococcal disease (IPD), caused by the approximately 91 serotypes of Streptococcus pneumoniae (PN), varies geographically and temporally as a result of changing epidemiology and vaccination patterns as well as due to regional measurement differences. Prevnar® (Pfizer), the first licensed pneumococcal conjugate vaccine (PCV), comprises polysaccharides (PS) from 7 serotypes conjugated to the mutant diphtheria toxin carrier protein, CRM197. In the United States and elsewhere, this vaccine has been highly efficacious in reducing the incidence of IPD caused by vaccine serotypes, however, the incidence of non-vaccine serotypes (e.g., 19A, 22F, and 33F) has increased, resulting in the need for vaccines with higher valencies. In response, 10- and 13-valent PCVs have recently been licensed. To further increase serotype coverage, we have developed a 15-valent PCV containing PS from serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F and 33F conjugated to CRM197 and formulated on aluminum phosphate adjuvant. Vaccine immunogenicity was evaluated in infant rhesus monkeys since they, like human infants, respond poorly to unconjugated PN PS. Infant (2-3 month old) rhesus monkeys were vaccinated three times with PCV-15 or Prevnar® at 2 month intervals, and serotype-specific IgG antibodies were measured using a multiarray electrochemiluminescence (ECL) assay. The results indicate that antibody responses to PCV-15 and Prevnar® were comparable for the 7 common serotypes and that post-vaccination responses to PCV-15 were >10-fold higher than baseline for the 8 additional serotypes. |
| |
Keywords: | IRM infant rhesus monkey IPD invasive pneumococcal disease PN Streptococcus pneumoniae PCV pneumococcal conjugate vaccine PS polysaccharides ECL electrochemiluminescence PnPS pneumococcal PS PRE pre-immune PD1 post dose-1 PD2 post dose-2 PD3 post dose-3 |
本文献已被 ScienceDirect PubMed 等数据库收录! |
|